#Bestinclass Recurrent #PMR RCT of #sarilumab v placebo. Nearly doubles sustained remission but maybe attenuating effect - flare difference over time? N=118. 🤷‍♀️ Dunno who I would use it in yet. LB0006 @RheumNow @eular_org #EULAR2022

Sarilumab in pts with relapsing PMR - Phase 3 trial Sarilumab +14 week steroid taper - higher sustained Remission than w/o sarilumab (28% vs 10%) Less flare occurrences Sarilumab noted to have higher incidences of neutropenia, arthralgia @RheumNow #EULAR2022 ABST#LB0006 https://t.co/SeetkBsYI3

Biosimilars and COVID vaccines have made nocebo more pertinent than ever. How do we combat it? First line is good communication, and the foot soldiers are the right phrases. Language matters. #EULAR2022 @RheumNow https://t.co/U0Chv9ia1G

Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change. In the 2022 version: JAKi now separate sentence following bDMARDs, with proviso to mention risk. Sometimes guidelines have to tell us what we’ve all inevitably been expecting #EULAR2022 @RheumNow https://t.co/RPbPNi3vcW

#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP

Does treating spondyloarthritis early matter? Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA axSpA - no difference in response between early vs. established disease @RheumNow #EULAR2022 ABST#POS0302

Sarilumab in PMR SAPHYR Phase 3 RCT Underpowered (<50% target recruitment) -% remission sustained from wk12 to wk 52 28% vs 10% PBO -Risk of flare reduced HR 0.56 -Improvement of several PROs No new safety signal LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo